

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Burden of Cancer in the General Surgical Population in the Eastern Region of Ghana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051741
Article Type:	Original research
Date Submitted by the Author:	05-Apr-2021
Complete List of Authors:	Olecki, Elizabeth; Penn State College of Medicine, General Surgery Ssentongo, Paddy; Penn State Health Milton S Hershey Medical Center, Dao, Joseph; Penn State College of Medicine Wong, William; Penn State College of Medicine Stahl, Kelly; Penn State College of Medicine, General Surgery Ofosu-Akromah, Richard; Eastern Regional Hospital, Surgery Amponsah-Manu, Foster; Eastern Regional Hospital, Surgery Pameijer, Colette; Penn State College of Medicine,
Keywords:	ONCOLOGY, SURGERY, PATHOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The Burden of Cancer in the General Surgical Population in the Eastern Region of**
5 **Ghana**
6
7
8
9

10 Elizabeth J Olecki¹, Paddy Ssentongo², Joseph Dao³, William G. Wong¹, Kelly A. Stahl¹,
11 Richard Ofosu-Akromah⁴, Foster Amponsah-Manu⁴, Colette R Pameijer¹
12
13
14
15
16
17
18

19 ¹Department of Surgery, The Pennsylvania State University, College of Medicine,
20 Hershey, PA
21
22

23 ²Department of Engineering Science and Mechanics, The Pennsylvania State
24 University, University Park, PA
25
26

27 ³The Pennsylvania State University, College of Medicine, Hershey, PA
28
29

30 ⁴Department of Surgery, Koforidua Regional Hospital, Ghana
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 ***Corresponding Author:***
50

51 Colette R. Pameijer, MD
52

53 The Pennsylvania State University
54
55
56
57
58
59
60

1
2
3 College of Medicare

4
5
6 Department of Surgery

7
8 500 University Drive

9
10 Cpameijer@pennstatehealth.psu.edu
11
12
13
14
15
16
17
18
19
20
21
22
23

24
25 **Abstract**
26
27
28
29

30 Objective: To estimate the surgical burden of malignant disease in the Eastern Region
31
32
33 of Ghana
34
35
36

37 Design: Descriptive cross-sectional study
38
39
40

41 Setting: Regional hospital in the Eastern Region of Ghana
42
43

44 Participants: Patients treated by the surgery department at Eastern Regional Hospital in
45
46
47 Koforidua, Ghana
48
49

50
51 Interventions: None
52
53
54
55
56
57
58
59
60

1
2
3
4 Primary and Secondary Outcome Measures: Primary outcome was incidence of
5
6
7 malignancy and secondary outcomes descriptive differences between patients who had
8
9
10 a benign indication for surgery compared to those with a malignant indication for
11
12
13
14 surgery.
15

16
17 Results: A total of 1,943 inpatient surgical procedures were performed from 2015-2017
18
19
20 with 13.4% (261) of all procedures ultimately performed for malignancy. Of all breast
21
22
23
24 procedures performed, 95.2% of procedures resulted in a malignant diagnosis. The
25
26
27
28 remaining subtypes of procedures had rates ranging from <1% to 41.2% of procedures
29
30
31 performed for malignant disease. Additionally, this study found over 13% of patients
32
33
34
35 admitted to the surgical service for breast cancer ultimately did not undergo a surgical
36
37
38 procedure.
39
40
41

42 Conclusion: This is the first study investigating the burden of malignant disease in the
43
44
45 Eastern Region of Ghana. We found a substantial prevalence of malignant disease in
46
47
48
49 the surgical population in this region. This information can be used to aid in future
50
51
52
53 medical resource planning in this region.
54
55
56
57
58
59
60

1
2
3
4 Trial Registration: Not Applicable
5
6

7 Article Summary:
8

- 9
- 10 • Strengths:
 - 11 ○ The burden of malignant disease in the Eastern Region of Ghana is
 - 12 currently unknown and this study represents the first study to characterize
 - 13 the incidence, distribution, and demographics of patients with malignant
 - 14 disease in this region.
 - 15
 - 16 ○ This study represents a novel method to estimate cancer burden in low-
 - 17 resource communities without comprehensive cancer registries using
 - 18 surgical log books and pathology records
 - 19
 - 20 ○ This study contains important results that can be used for resource
 - 21 allocation and capacity building of oncologic care programs.
 - 22
 - 23 • Limitations
 - 24 ○ Given the lack of cancer registries there is no way to characterize detailed
 - 25 oncologic, treatment, and overall survival data in this population.
 - 26
 - 27 ○ This study includes only patients treated by general surgery given limited
 - 28 records of other specialties and does not include patients with obvious
 - 29 advanced or metastatic disease who are not considered surgical
 - 30 candidates.
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60

1
2
3
4
5
6
7 **Keywords:**

8 Cancer, Ghana, Sub-Saharan Africa, Eastern Regional Hospital, Surgery
9
10

11
12
13
14 **Funding Statement:**

15 This research received no specific grant from any funding agency in the public,
16 commercial or not-for profit sectors.
17
18

19
20
21 **Competing Interests:**

22 None Declared
23
24
25
26
27
28
29
30

31 **Background**
32
33

34
35 Cancer is a major cause of morbidity and mortality worldwide with low-and-middle
36
37
38 income countries (LMIC) such as those in Sub-Saharan Africa shouldering a majority of
39
40
41 the burden of cancer related mortality (1). In 2016, out of 9 million cancer related
42
43
44 deaths, 70% occurred in LMIC (2). Historically, the burden of cancer has been
45
46
47
48 overshadowed in LMICs countries by infectious and neonatal mortalities. However, as
49
50
51
52 life expectancy has been progressively increasing in countries such as Ghana, attention
53
54
55
56 has been shifted toward preventing cancer-related deaths (3, 4). In Ghana, cancer-
57
58
59
60

1
2
3 related disease is currently the fifth leading cause of death at 58 deaths per 100,000
4
5
6
7 population annually (5) . While the current burden of cancer in Ghana is significant, the
8
9
10 International Agency for Cancer Research (IARC) estimates that cancer incidence and
11
12
13 mortality to double by 2040 (6), reinforcing the importance of understanding and
14
15
16
17 addressing burden of cancer related mortality in this region.
18
19
20

21 Contributing to this disproportionate burden of cancer in Ghana and other parts of
22
23 Sub-Saharan Africa is inadequate data and lack of centralized cancer registries. Cancer
24
25
26
27 registries are a basic but essential tool for understanding patterns of cancer and
28
29
30
31 developing effective programs regarding resource utilization (7). High quality cancer
32
33
34 registries such as the Cancer Incidence in Five Continents have provided valuable
35
36
37
38 information for high income continents such as North America, where over 95% of the
39
40
41
42 population is included in existing cancer databases. Data is inadequate for continents
43
44
45 such as Africa, where the proportion of population covered is less than 2% (8). While
46
47
48 attempts have been made to develop sustainable population based cancer registries
49
50
51
52 (PBCR) in Ghana, inadequate funding, lack of personnel, insufficient coordination of
53
54
55
56 reporting sources and the lack of available census data have made it difficult to
57
58
59
60

1
2
3 implement (9, 10). Currently the only existing PBCR in Ghana is the Kumasi Cancer
4
5
6
7 Registry, which was established in 2012 and collects cancer data from Komfo Anokye
8
9
10 Teaching Hospital and Kumasi South Regional Hospital (11). In the absence of PBCRs,
11
12
13 the majority of cancer incidence estimates for Ghana are based on mathematical
14
15
16
17 modelling which includes prevalence of risk factors and the use of data from other
18
19
20
21 countries in Sub-Saharan Africa (12).
22
23

24
25 Despite the known growing burden of cancer in Sub-Saharan Africa, the lack of
26
27
28 cancer registries along with limited understanding of the incidence and distribution of
29
30
31 different tumor types makes it difficult to allocate resources for early detection and
32
33
34 treatment (10, 13). Limited existing research has shown that a majority of patients with
35
36
37
38 cancer in Ghana present with advanced disease (14-16), and often require surgical
39
40
41
42 intervention. In fact, an existing cancer registry found that over 50% of cancers treated
43
44
45
46 at Komfo Anokye Teaching Hospital in Kumasi were treated by surgical resection only
47
48
49 and never received medical or radiation oncology treatments (10, 17). This is
50
51
52 concerning as the cancer registry initially collected information only from the medical
53
54
55
56
57
58
59
60

1
2
3 oncology department, resulting in a majority of the cancer cases inadvertently being left
4
5
6
7 out of the registry.
8
9

10 Given both the unknown burden of cancer outside of large cities in Ghana, as well
11
12
13
14 as the likely significant surgical burden of cancer related disease, the aim of this study
15
16
17 was to investigate the surgical cancer burden in the suburban/rural setting of Ghana's
18
19
20 Eastern Region. We hypothesized that there is a high burden of cancer related disease
21
22
23 affecting the population of Ghana's Eastern Region, and that a substantial proportion of
24
25
26
27 general surgery resources are currently being utilized to treat malignant disease. By
28
29
30 using data obtained from the inpatient general surgical service at Eastern Regional
31
32
33
34 Hospital (ERH), a large referral center for the Eastern Region of Ghana, our study aims
35
36
37
38 to estimate the incidence and burden of cancer related surgeries from 2015-2017 at this
39
40
41
42 institution.
43
44
45
46
47
48

49 **Methods:**

50
51
52 **Data Source:**
53
54
55
56
57
58
59
60

1
2
3
4 Surgical logbooks and the electronic medical record at Eastern Regional Hospital
5
6
7 (ERH) in Koforidua, Ghana were reviewed for all surgical admissions from 2015-2017 to
8
9
10 create a database of surgical patients. Demographic information including age, sex,
11
12
13 admitting diagnosis and surgical procedure performed were available within the
14
15
16 database. Primary surgical procedures for potentially malignant disease were grouped
17
18
19 into one of seven categories including gastric, soft tissue, biliary/hepatic, colon/rectal,
20
21
22 breast, thyroid, or other. Any patient admitted to the inpatient surgical service at ERH
23
24
25 between 2015-2017 and who had a procedure with general surgery was included in the
26
27
28 database. Men, women and children were included in this study. Patients having
29
30
31 gynecological or urologic surgery were excluded. Patients who did not have surgery or if
32
33
34 the procedure was not recorded were excluded (**Figure 1**).

35
36
37
38
39
40
41
42 Data regarding pathologic information was obtained directly from pathology
43
44
45 records. All pathology for ERH is performed at the neighboring hospital, St. Joseph
46
47
48 Orthopaedic Hospital. After any surgical procedure that results in a specimen that is
49
50
51 appropriate for pathologic evaluation, patients are asked to transport the specimen and
52
53
54 must pay an additional fee to St. Joseph Orthopaedic Hospital. Pathologic results are
55
56
57
58
59
60

1
2
3 then given directly to the patient or family member and must be physically brought to
4
5
6
7 their subsequent follow-up appointment with the operating surgeon at ERH. There is
8
9
10 inconsistent inclusion of pathology reports in medical records, thus all pathology reports
11
12
13 recorded at St. Joseph Orthopaedic hospital for procedures performed at ERH were
14
15
16 examined from 2015-2017. Any pathologic reports of malignancy were obtained and
17
18
19 included in this study except for gynecological and urologic tumors. Only patients
20
21
22 admitted to the surgical ward were included in this study, with all outpatient procedures
23
24
25 and patients admitted to medical, gynecological, and pediatric wards excluded from this
26
27
28 study. Approval for use of the data was given by the institutional review board at The
29
30
31 Pennsylvania State University College of Medicine (STUDY00011242) as well as by
32
33
34 ERH ethical review board.
35
36
37
38
39
40
41
42
43
44

45 Patient and Public Involvement:

46
47

48 It was not appropriate or possible to involve patients or the public in the design, or
49
50
51
52 conduct, or reporting, or dissemination plans of our research
53
54
55
56
57
58
59
60

Statistics:

Descriptive statistics including mean and standard deviation or median and interquartile range for normally distributed and skewed continuous data were reported.

Categorical variables were expressed as frequencies and percentages. The incidence of cancer diagnosis by type of procedure was calculated by determining the number of malignancies identified by pathology report divided by the overall number of surgical procedures performed during the same time period.

Results:

There were 4,014 admissions to the surgical service from 2015-2017. After excluding gynecological and urological procedures, a total of 3,713 admissions for the general surgical service occurred during this time period, with 1,943 having recorded surgical procedures. The 1,943 patients with recorded surgical procedures included 56 gastric procedures, 253 soft tissue procedures, 57 biliary/hepatic procedures, 119 colon/rectal procedures, 83 breast procedures, 136 thyroid procedures, and 1,239

1
2
3 classified as other, most commonly hernia repair or appendectomy. The mean age,
4
5
6
7 gender, and insurance status distribution can be seen in **Table 1**.
8
9

10 Information obtained from pathology reports is presented in **Table 2**. A total of
11
12
13
14 261 pathology reports during 2015-2017 revealed a definitive malignant diagnosis. This
15
16
17 indicates that 134 per 1000 surgeries performed at EHR during this time period were
18
19
20 performed due to a malignant diagnosis with confirmed pathologic evaluation. When
21
22
23 including all patients admitted to and treated by the surgical service, with or without
24
25
26 documented surgical intervention, this study found that 70 per 1000 surgical admissions
27
28
29 had a diagnosis of malignancy that was pathologically confirmed.
30
31
32
33
34

35 When further investigating categories of surgical procedure, the highest
36
37
38 incidence of malignancy was found to be in those undergoing inpatient breast
39
40
41 procedures. 95.2% (79/83) of all breast procedures resulted in a diagnosis of breast
42
43
44 cancer. Of those with a diagnosis of breast cancer, 97.5% were female with an average
45
46
47 age of 54 years old (SD 13.44).
48
49
50
51

52 A total of 119 colon, rectal, and anal procedures were performed from 2015-2017
53
54
55 resulting in 49 with a confirmed malignant diagnosis. This means that 41.2% of all
56
57
58
59
60

1
2
3 colon, rectal, and anal procedures were ultimately performed for malignant disease. The
4
5
6
7 majority of these cancers were determined to be colon adenocarcinoma (29/49), 15/49
8
9
10 were for adenocarcinoma located in the rectum, 3/49 were performed for squamous cell
11
12
13 carcinoma of the anus, and 2/49 were indeterminate recto-anal malignancy. Colorectal
14
15
16 cancers were evenly distributed between males and females with a slight female
17
18
19 predominance (42.9% and 55.1% respectively). Those who were diagnosed with
20
21
22 colorectal malignancy were on average older with a mean age of 55.1 years (SD 16.4)
23
24
25 compared to the mean age of 43.5 years (SD 18.23) of all those undergoing colon and
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

rectal surgical procedures.

Another surgical procedure found to have high rates of final malignant diagnosis
were gastric procedures, with 30.4% (17/56) of all gastric procedures performed during
this time period resulting in malignant diagnosis. Of the 17 patients with pathologic
evidence of gastric malignancy, there was similar incidence in male and female
patients. The mean age of patients diagnosed with gastric malignancy was 58.3 (SD
19.77) compared to 51.4 (SD 20.37) in those undergoing all gastric surgical procedures.

1
2
3
4 The remaining types of procedures had malignancy rates of 10.3% (14/136) for
5
6
7 all thyroid procedures, 8.8% (5/57) of all biliary procedures, 8.3% (21/253) of all soft
8
9
10 tissue procedures, and less than 1% (12/1,239) of all other procedures resulting in a
11
12
13 malignant diagnosis. Demographic information regarding age and gender can be seen
14
15
16
17 in **Table 2**.

18
19
20
21 Further investigation into patients with an admitting diagnosis of breast disease,
22
23
24 including individuals with breast cancer, breast abscess, breast cyst, and breast lumps,
25
26
27 is presented in **Table 3**. There were 145 patients admitted with a diagnosis related to
28
29
30 breast disease with 57.2% (83/145) known to have breast cancer or suspected to have
31
32
33 breast cancer based on physical exam resulting in an admitting diagnosis of “breast
34
35
36 cancer”. Of the 83 patients with an admitting diagnosis of breast cancer, 81.0% (68/83)
37
38
39 had surgical treatment with mastectomy. No documented surgical procedure was
40
41
42 performed in 13.1% (11/84) of those admitted with a diagnosis of breast cancer.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Discussion:
57
58
59
60

1
2
3
4 The findings from this study represent important data that can be used locally,
5
6
7 regionally, and nationally to better identify and treat patients with oncologic disease and
8
9
10 allocate limited medical resources. Specifically, at ERH the results from this study can
11
12
13
14 be used by physicians treating individual patients as well as by administration for
15
16
17 resource planning. Given that a majority of patients with final malignant disease were
18
19
20 suspected to have benign disease preoperatively based upon admitting diagnosis, the
21
22
23 knowledge of incidence of malignancy and demographic information presented in this
24
25
26
27 study could be used to guide surgeon decision making about operative intervention on
28
29
30 possible malignant disease. For example, awareness that currently greater than 30% of
31
32
33
34 all gastric procedures that are performed at ERH are for malignancy and that malignant
35
36
37 diagnosis was found more often in older patients allows for consideration of further
38
39
40
41 diagnostic work-up or referral to oncology prior to surgical intervention. On a larger
42
43
44 health system scale, given the high burden of cancer at ERH demonstrated by this
45
46
47
48 study, future development of local chemotherapy and radiation therapy programs should
49
50
51
52 be considered a priority.
53
54
55
56
57
58
59
60

1
2
3
4 Without an existing uniform population-based cancer registry system in Ghana
5
6
7 (11), distribution of resources and development of medical infrastructure to enhance
8
9
10 access to treatment of cancer is challenging. Unfortunately, formal population-based
11
12
13 cancer registries are associated with significant cost and time to develop. Because of
14
15
16 this, LMIC countries such as Ghana must often rely on basic estimates of cancer
17
18
19 burden when developing plans for the distribution and development of systems focused
20
21
22 on cancer treatment (18). While there have been significant advancements regarding
23
24
25 planned development of cancer registries in primarily large, urban hospitals (9) such as
26
27
28 those in Kumasi (10) and Accra (19), the burden of malignancy faced by smaller
29
30
31 suburban and rural hospitals, with extremely limited resources, is unknown and is
32
33
34 unlikely to be captured by formal cancer registries for the foreseeable future. With this
35
36
37 in mind, this study demonstrates the current need for cancer resources in the Eastern
38
39
40 Region of Ghana. Today patients who require specialized oncologic care must travel to
41
42
43 another region for care, with a majority of patients from ERH referred to Korle Bu for
44
45
46 treatment. These facilities are hours away from the patient's home and treatment is
47
48
49 often delayed due to the high volume of patients that are referred to these limited
50
51
52
53
54
55
56
57
58
59
60

1
2
3 specialized centers. With no regional access to oncology care, many patients are
4
5
6
7 treated with systemic chemotherapy prescribed and managed by the operating surgeon
8
9
10 at ERH, which likely accounts for the patients admitted to the surgical service with a
11
12
13 diagnosis of breast cancer who then did not undergo any surgical procedure observed
14
15
16 in this study. This study demonstrates that small, regional hospitals have a substantial
17
18
19 and diverse oncologic burden, and are in dire need of infrastructure, resources, and
20
21
22 specialized personnel to treat patients diagnosed with cancer.
23
24
25
26
27

28 While this study contains important data regarding the burden of malignancy in
29
30 this geographic area, there are limitations that must be considered when interpreting
31
32
33 this data. As there is currently no existing cancer registry capturing malignancies
34
35
36 treated in this region, we do not have access to many demographic, oncologic,
37
38
39 treatment, and overall survival data. This additional information would be helpful for
40
41
42 further planning and resource utilization. Additionally, while a majority of patients
43
44
45 presenting with malignancy are admitted to and treated by the surgical service, this
46
47
48 study does not capture cancer patients treated by other specialties, most notably
49
50
51
52
53
54
55
56
57
58
59
60 gynecological cancers. Also, patients admitted to the surgical service with obvious

1
2
3 advanced or metastatic disease are not considered surgical candidates, and are not
4
5
6
7 accounted for in these data. Lastly, because patients must transport and pay additional
8
9
10 fees in order to obtain pathology results, there are pathologic specimens that are never
11
12
13 examined and recorded. Currently, it is estimated that about 20% of all specimens that
14
15
16 surgeons request pathologic evaluation do not undergo pathologic evaluation due to
17
18
19 patient noncompliance or inability to afford the extra associated fee. Missing pathologic
20
21
22 results could lead to underestimation of the true incidence of malignancy treated
23
24
25 surgically at ERH.
26
27
28
29
30
31
32
33
34

35 Conclusion:

36
37
38 This is the first study to investigate the cancer burden in Ghana's Eastern Region. This
39
40
41 study reveals that over 13% of all surgical interventions were performed in patients with
42
43
44 malignant disease. Rates of malignant diagnosis vary by type of procedure performed,
45
46
47 but are very high in patients undergoing breast, colorectal, and gastric procedures. This
48
49
50 study is a preliminary evaluation demonstrating the substantial cancer burden in the
51
52
53 Eastern Region of Ghana and the burden of oncologic disease on general surgeons.
54
55
56
57
58
59
60

1
2
3 Information from this study can be used to improve access to oncologic directed
4
5
6
7 treatments in this region and plan future studies to further evaluate the burden of cancer
8
9
10 and cancer related diseases at local and regional healthcare facilities in Sub-Saharan
11
12
13
14 Africa.

15
16
17
18
19
20 List of Abbreviations:

21
22 LMIC-low-and-middle income countries

23
24 IARC-International Agency for Cancer Research

25
26 ERH-Eastern Regional Hospital

27
28 SD- Standard Deviation

- 29
30
31
32
33
34
35
36 • Authors' contributions

37
38
39 EO was involved in study design, data collection, data analysis, interpretation of
40 data, majority of manuscript authorship, and critical review and editing of
41 manuscript

42
43
44 PS was involved in study design, data collection, data analysis, interpretation of
45 data, and critical review and editing of manuscript

46
47
48 JD was involved in study design, data collection, data analysis, critical review
49 and editing of manuscript

50
51
52 WW was involved in study design, data collection, data analysis, critical review
53 and editing of manuscript

1
2
3
4 KS was involved in study design, data collection, data analysis, critical review
5 and editing of manuscript

6
7 RO was involved in interpretation of data, critical review and editing of
8 manuscript.
9

10 FA was involved in study design, interpretation of data, critical review and editing
11 of manuscript, and supervised the entirety of the project.

12
13 CP was involved in study design, interpretation of data, critical review and editing
14 of manuscript, and supervised the entirety of the project.
15
16
17

18
19 All authors read and approved the final manuscript
20
21
22
23

24
25 • Acknowledgements

26
27
28 Not Applicable
29
30
31
32

33
34 References:

- 35 1. Shah SC, Kayamba V, Peek RM, Heimbürger D. Cancer Control in Low- and Middle-Income
36 Countries: Is It Time to Consider Screening? *J Glob Oncol.* 2019;5:1-8.
37 2. The Global Cancer Burden American Cancer Society 2020 [Available from:
38 <https://www.cancer.org/health-care-professionals/our-global-health-work/global-cancer-burden.html>.
39 3. National Policy for the Prevention and Control of Chronic Non-Communicable Disease in Ghana
40 Ministry of Health 2012 [Available from: [https://www.iccp-
41 portal.org/sites/default/files/plans/national_policy_for_the_prevention_and_control_of_chronic_non-
42 communicable_diseases_in_ghana\(1\).pdf](https://www.iccp-portal.org/sites/default/files/plans/national_policy_for_the_prevention_and_control_of_chronic_non-communicable_diseases_in_ghana(1).pdf).
43 4. de-Graft Aikins A, Addo J, Ofei F, Bosu W, Agyemang C. Ghana's burden of chronic non-
44 communicable diseases: future directions in research, practice and policy. *Ghana Med J.* 2012;46(2
45 Suppl):1-3.
46 5. Global Burden of Disease Cause Patterns 2016 Institute for Health Metrics and Evaluation
47 [Available from: <https://vizhub.healthdata.org/gbd-compare/>.
48 6. Ferlay J SI, Ervik M, et al. Cancer Incidence and Mortality Worldwide [Available from:
49 <https://gco.iarc.fr/tomorrow/home>.
50 7. National Program of Cancer Registries Cancer Surveillance System Rationale and Approach. In:
51 Control CfD, editor. 1999.
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. *Int J Cancer*. 2015;137(9):2060-71.
9. Yarney J, Ohene Oti NO, Calys-Tagoe BNL, Gyasi RK, Agyeman Duah I, Akoto-Aidoo C, et al. Establishing a Cancer Registry in a Resource-Constrained Region: Process Experience From Ghana. *JCO Glob Oncol*. 2020;6:610-6.
10. O'Brien KS, Soliman AS, Awuah B, Jiggae E, Osei-Bonsu E, Quayson S, et al. Establishing effective registration systems in resource-limited settings: cancer registration in Kumasi, Ghana. *J Registry Manag*. 2013;40(2):70-7.
11. Laryea DO, Awuah B, Amoako YA, Osei-Bonsu E, Dogbe J, Larsen-Reindorf R, et al. Cancer incidence in Ghana, 2012: evidence from a population-based cancer registry. *BMC Cancer*. 2014;14:362.
12. Amoako YA, Awuah B, Larsen-Reindorf R, Awittor FK, Kyem G, Ofori-Boadu K, et al. Malignant tumours in urban Ghana: evidence from the city of Kumasi. *BMC Cancer*. 2019;19(1):267.
13. Paul Opoku BA, Kofi Nyarko. Cancer Registration in Low-Resourced Settings: Practice and Recommendations. *Afr J Haematol Oncol*. 2010;1(4):129-37.
14. Kitcher E, Yarney J, Gyasi R, Cheyuo C. Laryngeal cancer at the korle bu teaching hospital accra ghana. *Ghana Med J*. 2006;40(2):45-9.
15. Clegg-Lampsey J, Hodasi W. A study of breast cancer in korle bu teaching hospital: assessing the impact of health education. *Ghana Med J*. 2007;41(2):72-7.
16. Martei YM, Vanderpuye V, Jones BA. Fear of Mastectomy Associated with Delayed Breast Cancer Presentation Among Ghanaian Women. *Oncologist*. 2018;23(12):1446-52.
17. Espina C, McKenzie F, Dos-Santos-Silva I. Delayed presentation and diagnosis of breast cancer in African women: a systematic review. *Ann Epidemiol*. 2017;27(10):659-71.e7.
18. Hanna TP, Kangolle AC. Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency. *BMC Int Health Hum Rights*. 2010;10:24.
19. Calys-Tagoe BN, Yarney J, Kenu E, Amanhyia NA, Enchill E, Obeng I. Profile of cancer patients' seen at Korle Bu teaching hospital in Ghana (a cancer registry review). *BMC Res Notes*. 2014;7:577.

Figure 1. Flow Chart of patients included in study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

For peer review only

Table 1. Demographic Features of Patients Undergoing Any Surgical Procedures

	Gastric Procedure (N=56)	Soft Tissue Procedure (N=253)	Biliary/Hepatic Procedure (N=57)	Colon/Rectal Procedure (N=119)	Breast Procedure (N=83)	Thyroid Procedure (N=136)	Other Procedure (N=1,239)
Gender							
FEMALE	19 (33.9%)	94 (37.2%)	37 (64.9%)	24 (20.2%)	80 (96.4%)	126 (92.6%)	433 (34.9%)
MALE	37 (66.1%)	159 (62.8%)	20 (35.1%)	95 (79.8%)	3 (3.6%)	10 (7.4%)	806 (65.1%)
Age							
Mean (SD)	51.4 (20.37)	47.3 (21.73)	52.6 (20.24)	43.5 (18.23)	54.0 (13.44)	47.0 (13.10)	40.6 (20.40)
Median	58.0	45.0	51.0	42.0	54.0	47.0	38.0
Interquartile range	35.5, 65.5	31.0, 66.0	40.0, 68.0	30.0, 52.0	46.0, 61.0	38.0, 57.5	25.0, 55.0
Range	(0.0-88.0)	(1.0-94.0)	(7.0-96.0)	(5.0-97.0)	(15.0-94.0)	(16.0-83.0)	(0.0-140.0)
Insurance Status							
No	15 (26.8%)	45 (17.8%)	9 (15.8%)	41 (34.5%)	15 (18.1%)	7 (5.1%)	504 (40.7%)
Yes	41 (73.2%)	208 (82.2%)	48 (84.2%)	78 (65.5%)	68 (81.9%)	129 (94.9%)	735 (59.3%)

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Demographic Features of All Patients with Malignant Diagnosis

	Gastric	Soft Tissue	Biliary/Hepatic	Colon/Rectal	Breast	Thyroid	Other	Total
Number	17	21	5	49	79	14	12	261
Gender								
Female	9 (52.9%)	11 (52.4%)	2 (40%)	27 (55.1%)	77 (97.5%)	13 (92.9%)	7 (58.3%)	
Male	8 (47%)	10 (47.6%)	3 (60%)	21 (42.9%)	2 (2.5%)	1 (7.1%)	5 (41.7%)	
Age								
Mean (SD)	58.3 (19.77)	49.2 (16.3)	56.6 (6.4)	55.1 (16.4)	50.0 (14.7)	44.7 (14.8)	54.3 (21.6)	
Median	59.5	48.0	57	58	48	44	53	
Range	(28-97)	(29-80)	(45-63)	(15-85)	(4-79)	(13-68)	(20-94)	

Table 3. Details of those with admitting diagnosis related to breast disease

Admitting Diagnosis	145
Breast Abscess	29
Breast Cyst	5
Breast Lump	28
Breast Cancer	83

Table 3. Details of those with admitting diagnosis related to breast disease

Surgical Procedure Performed for those with Breast Cancer	83
Mastectomy	68 (81.0%)
Chest Tube Placement	1 (1.2%)
Emergency Tracheostomy	1 (1.2%)
Palliative Excisional Procedure	3 (3.8%)
No Surgical Procedure	11 (13.1%)

For peer review only




Figure 1. Flow Chart of patients included in study.

Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Page
	Reporting Item	Number
Title and abstract		
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1

1	Abstract	#1b	Provide in the abstract an informative and balanced summary	2
2				
3				
4			of what was done and what was found	
5				
6	Introduction			
7				
8				
9				
10	Background /	#2	Explain the scientific background and rationale for the	4
11	rationale		investigation being reported	
12				
13				
14				
15	Objectives	#3	State specific objectives, including any prespecified	5
16			hypotheses	
17				
18				
19				
20	Methods			
21				
22				
23	Study design	#4	Present key elements of study design early in the paper	6
24				
25				
26	Setting	#5	Describe the setting, locations, and relevant dates, including	6
27			periods of recruitment, exposure, follow-up, and data	
28			collection	
29				
30				
31				
32				
33				
34	Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of	6
35			selection of participants.	
36				
37				
38				
39				
40		#7	Clearly define all outcomes, exposures, predictors, potential	6
41			confounders, and effect modifiers. Give diagnostic criteria, if	
42			applicable	
43				
44				
45				
46				
47	Data sources /	#8	For each variable of interest give sources of data and details	6
48	measurement		of methods of assessment (measurement). Describe	
49			comparability of assessment methods if there is more than	
50			one group. Give information separately for for exposed and	
51			unexposed groups if applicable.	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Bias	#9	Describe any efforts to address potential sources of bias	11
2				
3				
4	Study size	#10	Explain how the study size was arrived at	7
5				
6				
7	Quantitative	#11	Explain how quantitative variables were handled in the	6
8	variables		analyses. If applicable, describe which groupings were	
9			chosen, and why	
10				
11				
12				
13				
14				
15	Statistical	#12a	Describe all statistical methods, including those used to	6
16	methods		control for confounding	
17				
18				
19				
20	Statistical	#12b	Describe any methods used to examine subgroups and	6
21	methods		interactions	
22				
23				
24				
25				
26	Statistical	#12c	Explain how missing data were addressed	6
27	methods			
28				
29				
30				
31	Statistical	#12d	If applicable, describe analytical methods taking account of	6
32	methods		sampling strategy	
33				
34				
35				
36	Statistical	#12e	Describe any sensitivity analyses	6
37	methods			
38				
39				
40				
41				
42	Results			
43				
44				
45	Participants	#13a	Report numbers of individuals at each stage of study—eg	7
46			numbers potentially eligible, examined for eligibility,	
47			confirmed eligible, included in the study, completing follow-	
48			up, and analysed. Give information separately for for	
49			exposed and unexposed groups if applicable.	
50				
51				
52				
53				
54				
55				
56				
57	Participants	#13b	Give reasons for non-participation at each stage	7
58				
59				
60				

1	Participants	#13c	Consider use of a flow diagram	7
2				
3				
4	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	7
5			clinical, social) and information on exposures and potential	
6			confounders. Give information separately for exposed and	
7			unexposed groups if applicable.	
8				
9				
10				
11				
12				
13				
14	Descriptive data	#14b	Indicate number of participants with missing data for each	7
15			variable of interest	
16				
17				
18				
19	Outcome data	#15	Report numbers of outcome events or summary measures.	7
20			Give information separately for exposed and unexposed	
21			groups if applicable.	
22				
23				
24				
25				
26				
27	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-	7
28			adjusted estimates and their precision (eg, 95% confidence	
29			interval). Make clear which confounders were adjusted for	
30			and why they were included	
31				
32				
33				
34				
35				
36				
37	Main results	#16b	Report category boundaries when continuous variables were	8
38			categorized	
39				
40				
41				
42	Main results	#16c	If relevant, consider translating estimates of relative risk into	8
43			absolute risk for a meaningful time period	
44				
45				
46				
47				
48	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups	8
49			and interactions, and sensitivity analyses	
50				
51				
52				
53	Discussion			
54				
55				
56	Key results	#18	Summarise key results with reference to study objectives	10
57				
58				
59				
60				

1	Limitations	#19	Discuss limitations of the study, taking into account sources	11
2			of potential bias or imprecision. Discuss both direction and	
3			magnitude of any potential bias.	
4				
5				
6				
7				
8				
9	Interpretation	#20	Give a cautious overall interpretation considering objectives,	11
10			limitations, multiplicity of analyses, results from similar	
11			studies, and other relevant evidence.	
12				
13				
14				
15				
16	Generalisability	#21	Discuss the generalisability (external validity) of the study	11
17			results.	
18				
19				
20				
21				
22	Other Information			
23				
24				
25	Funding	#22	Give the source of funding and the role of the funders for the	3
26			present study and, if applicable, for the original study on	
27			which the present article is based	
28				
29				
30				
31				
32				

33 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License
34 CC-BY. This checklist was completed on 26. March 2021 using <https://www.goodreports.org/>, a tool
35 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

The Burden of Cancer in the General Surgical Population in the Eastern Region of Ghana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051741.R1
Article Type:	Original research
Date Submitted by the Author:	15-Dec-2021
Complete List of Authors:	Olecki, Elizabeth; Penn State College of Medicine, General Surgery Ssentongo, Paddy; Penn State Health Milton S Hershey Medical Center, Dao, Joseph; Penn State College of Medicine Wong, William; Penn State College of Medicine Stahl, Kelly; Penn State College of Medicine, General Surgery Ofosu-Akromah, Richard; Eastern Regional Hospital, Surgery Amponsah-Manu, Foster; Eastern Regional Hospital, Surgery Pameijer, Colette; Penn State College of Medicine,
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Oncology, Global health
Keywords:	ONCOLOGY, SURGERY, PATHOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The Burden of Cancer in the General Surgical Population in the Eastern Region of**
5 **Ghana**
6
7
8
9

10 Elizabeth J Olecki¹, Paddy Ssentongo², Joseph Dao³, William G. Wong¹, Kelly A. Stahl¹,
11 Richard Ofosu-Akromah⁴, Foster Amponsah-Manu⁴, Colette R Pameijer¹
12
13
14
15
16
17
18

19 ¹Department of Surgery, The Pennsylvania State University, College of Medicine,
20 Hershey, PA
21
22

23 ²Department of Engineering Science and Mechanics, The Pennsylvania State
24 University, University Park, PA
25
26

27 ³The Pennsylvania State University, College of Medicine, Hershey, PA
28
29

30 ⁴Department of Surgery, Koforidua Regional Hospital, Ghana
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 ***Corresponding Author:***
50

51 Colette R. Pameijer, MD
52

53 The Pennsylvania State University
54
55
56
57
58
59
60

1
2
3 College of Medicare

4 Department of Surgery

5
6 500 University Drive

7
8 Cpameijer@pennstatehealth.psu.edu
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24
25 **Abstract**
26
27
28
29

30 **Objective:** To estimate the surgical burden of malignant disease in the Eastern Region
31
32
33 of Ghana
34
35

36
37 **Design:** Descriptive cross-sectional study
38
39

40
41 **Setting:** Regional hospital in the Eastern Region of Ghana
42
43

44 **Participants:** Patients treated by the surgery department at Eastern Regional Hospital in
45
46
47 Koforidua, Ghana
48
49

50
51 **Interventions:** None
52
53
54
55
56
57
58
59
60

1
2
3
4 Primary and Secondary Outcome Measures: Primary outcome was incidence of
5
6
7 malignancy and secondary outcomes descriptive differences between patients who had
8
9
10 a benign indication for surgery compared to those with a malignant indication for
11
12
13
14 surgery.
15

16
17 Results: A total of 1,943 inpatient surgical procedures were performed from 2015-2017
18
19
20 with 13.4% (261) of all procedures ultimately performed for malignancy. Of all breast
21
22
23
24 procedures performed, 95.2% of procedures resulted in a malignant diagnosis. The
25
26
27
28 remaining subtypes of procedures had rates ranging from <1% to 41.2% of procedures
29
30
31 performed for malignant disease. Additionally, this study found over 13% of patients
32
33
34
35 admitted to the surgical service for breast cancer ultimately did not undergo a surgical
36
37
38 procedure.
39
40

41
42 Conclusion: This is the first study investigating the burden of malignant disease in the
43
44
45 Eastern Region of Ghana. We found a substantial prevalence of malignant disease in
46
47
48
49 the surgical population in this region. This information can be used to aid in future
50
51
52
53 medical resource planning in this region.
54
55
56
57
58
59
60

1
2
3
4 Trial Registration: Not Applicable
5
6

7 Article Summary:
8

- 9
- 10 • Strengths:
 - 11 ○ The burden of malignant disease in the Eastern Region of Ghana is
 - 12 currently unknown and this study represents the first study to characterize
 - 13 the incidence, distribution, and demographics of patients with malignant
 - 14 disease in this region.
 - 15
 - 16 ○ This study represents a novel method to estimate cancer burden in low-
 - 17 resource communities without comprehensive cancer registries using
 - 18 surgical log books and pathology records
 - 19
 - 20 ○ This study contains important results that can be used for resource
 - 21 allocation and capacity building of oncologic care programs.
 - 22
 - 23 • Limitations
 - 24 ○ Given the lack of cancer registries there is no way to characterize detailed
 - 25 oncologic, treatment, and overall survival data in this population.
 - 26
 - 27 ○ This study includes only patients treated by general surgery given limited
 - 28 records of other specialties and does not include patients with obvious
 - 29 advanced or metastatic disease who are not considered surgical
 - 30 candidates.
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60

1
2
3
4
5
6
7 **Keywords:**

8 Cancer, Ghana, Sub-Saharan Africa, Eastern Regional Hospital, Surgery
9
10

11
12
13
14 **Funding Statement:**

15 This research received no specific grant from any funding agency in the public,
16 commercial or not-for profit sectors.
17
18

19
20
21 **Competing Interests:**

22 None Declared
23
24
25
26
27
28
29
30

31 **Background**
32
33
34

35 Cancer is a major cause of morbidity and mortality worldwide with low-and-middle
36 income countries (LMIC) such as those in Sub-Saharan Africa shouldering a majority of
37
38 the burden of cancer related mortality (1). In 2016, out of 9 million cancer related
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
has been shifted toward preventing cancer-related deaths (3, 4). In Ghana, cancer-

1
2
3 related disease is currently the fifth leading cause of death at 58 deaths per 100,000
4
5
6
7 population annually (5) . While the current burden of cancer in Ghana is significant, the
8
9
10 International Agency for Cancer Research (IARC) estimates that cancer incidence and
11
12
13 mortality to double by 2040 (6), reinforcing the importance of understanding and
14
15
16
17 addressing burden of cancer related mortality in this region.
18
19
20

21 Contributing to this disproportionate burden of cancer in Ghana and other parts of
22
23 Sub-Saharan Africa is inadequate data and lack of centralized cancer registries. Cancer
24
25 registries are a basic but essential tool for understanding patterns of cancer and
26
27
28 developing effective programs regarding resource utilization (7). High quality cancer
29
30
31 registries such as the Cancer Incidence in Five Continents have provided valuable
32
33
34 information for high income continents such as North America, where over 95% of the
35
36
37 population is included in existing cancer databases. Data is inadequate for continents
38
39
40 such as Africa, where the proportion of population covered is less than 2% (8). While
41
42
43 attempts have been made to develop sustainable population based cancer registries
44
45
46 (PBCR) in Ghana, inadequate funding, lack of personnel, insufficient coordination of
47
48
49 reporting sources and the lack of available census data have made it difficult to
50
51
52
53
54
55
56
57
58
59
60

1
2
3 implement (9, 10). Currently the only existing PBCR in Ghana is the Kumasi Cancer
4
5
6
7 Registry, which was established in 2012 and collects cancer data from Komfo Anokye
8
9
10 Teaching Hospital and Kumasi South Regional Hospital (11). In the absence of PBCRs,
11
12
13 the majority of cancer incidence estimates for Ghana are based on mathematical
14
15
16
17 modelling which includes prevalence of risk factors and the use of data from other
18
19
20
21 countries in Sub-Saharan Africa (12).
22
23

24
25 Despite the known growing burden of cancer in Sub-Saharan Africa, the lack of
26
27
28 cancer registries along with limited understanding of the incidence and distribution of
29
30
31 different tumor types makes it difficult to allocate resources for early detection and
32
33
34 treatment (10, 13). Limited existing research has shown that a majority of patients with
35
36
37
38 cancer in Ghana present with advanced disease (14-16), and often require surgical
39
40
41
42 intervention. In fact, an existing cancer registry found that over 50% of cancers treated
43
44
45
46 at Komfo Anokye Teaching Hospital in Kumasi were treated by surgical resection only
47
48
49 and never received medical or radiation oncology treatments (10, 17). This is
50
51
52 concerning as the cancer registry initially collected information only from the medical
53
54
55
56
57
58
59
60

1
2
3 oncology department, resulting in a majority of the cancer cases inadvertently being left
4
5
6
7 out of the registry.
8
9

10 Given both the unknown burden of cancer outside of large cities in Ghana, as well
11
12
13
14 as the likely significant surgical burden of cancer related disease, the aim of this study
15
16
17 was to investigate the surgical cancer burden in the suburban/rural setting of Ghana's
18
19
20 Eastern Region. We hypothesized that there is a high burden of cancer related disease
21
22
23 affecting the population of Ghana's Eastern Region, and that a substantial proportion of
24
25
26
27 general surgery resources are currently being utilized to treat malignant disease. By
28
29
30 using data obtained from the inpatient general surgical service at Eastern Regional
31
32
33
34 Hospital (ERH), a large referral center for the Eastern Region of Ghana, our study aims
35
36
37
38 to estimate the incidence and burden of cancer related surgeries from 2015-2017 at this
39
40
41
42 institution.
43
44
45
46
47
48

49 **Methods:**

50
51
52 **Data Source:**
53
54
55
56
57
58
59
60

1
2
3
4 Surgical logbooks and the electronic medical record at Eastern Regional Hospital
5
6
7 (ERH) in Koforidua, Ghana were reviewed for all surgical admissions from 2015-2017 to
8
9
10 create a database of surgical patients. Demographic information including age, sex,
11
12
13
14 admitting diagnosis and surgical procedure performed were available within the
15
16
17
18 database. Primary surgical procedures for potentially malignant disease were grouped
19
20
21 into one of seven categories including gastric, soft tissue, biliary/hepatic, colon/rectal,
22
23
24 breast, thyroid, or other. Any patient admitted to the inpatient surgical service at ERH
25
26
27
28 between 2015-2017 and who had a procedure with general surgery was included in the
29
30
31 database. Men, women and children were included in this study. Patients having
32
33
34 gynecological or urologic surgery were excluded. Patients who did not have surgery or if
35
36
37
38 the procedure was not recorded were excluded (**Figure 1**).

39
40
41
42 Data regarding pathologic information was obtained directly from pathology
43
44
45 records. All pathology for ERH is performed at the neighboring hospital, St. Joseph
46
47
48 Orthopaedic Hospital. After any surgical procedure that results in a specimen that is
49
50
51
52 appropriate for pathologic evaluation, patients are asked to transport the specimen and
53
54
55
56 must pay an additional fee to St. Joseph Orthopaedic Hospital. Pathologic results are
57
58
59

1
2
3 then given directly to the patient or family member and must be physically brought to
4
5
6
7 their subsequent follow-up appointment with the operating surgeon at ERH. There is
8
9
10 inconsistent inclusion of pathology reports in medical records, thus all pathology reports
11
12
13 recorded at St. Joseph Orthopaedic hospital for procedures performed at ERH were
14
15
16 examined from 2015-2017. Any pathologic reports of malignancy were obtained and
17
18
19 included in this study except for gynecological and urologic tumors. Only patients
20
21
22 admitted to the surgical ward were included in this study, with all outpatient procedures
23
24
25 and patients admitted to medical, gynecological, and pediatric wards excluded from this
26
27
28 study. Approval for use of the data was given by the institutional review board at The
29
30
31 Pennsylvania State University College of Medicine (STUDY00011242) as well as by
32
33
34 ERH ethical review board.
35
36
37
38
39
40
41
42
43
44

45 Patient and Public Involvement:

46
47

48 It was not appropriate or possible to involve patients or the public in the design, or
49
50
51
52 conduct, or reporting, or dissemination plans of our research
53
54
55
56
57
58
59
60

Statistics:

Descriptive statistics including mean and standard deviation or median and interquartile range for normally distributed and skewed continuous data were reported. Categorical variables were expressed as frequencies and percentages. The incidence of cancer diagnosis by type of procedure was calculated by determining the number of malignancies identified by pathology report divided by the overall number of surgical procedures performed during the same time period.

Results:

There were 4,014 admissions to the surgical service from 2015-2017. After excluding gynecological and urological procedures, a total of 3,713 admissions for the general surgical service occurred during this time period, with 1,943 having recorded surgical procedures. The 1,943 patients with recorded surgical procedures included 56 gastric procedures, 253 soft tissue procedures, 57 biliary/hepatic procedures, 119 colon/rectal procedures, 83 breast procedures, 136 thyroid procedures, and 1,239

1
2
3 classified as other, most commonly hernia repair or appendectomy. The mean age,
4
5
6
7 gender, and insurance status distribution can be seen in **Table 1**.
8
9

10 Information obtained from pathology reports is presented in **Table 2**. A total of
11
12
13
14 261 pathology reports during 2015-2017 revealed a definitive malignant diagnosis. This
15
16
17 indicates that 134 per 1000 surgeries performed at EHR during this time period were
18
19
20 performed due to a malignant diagnosis with confirmed pathologic evaluation. When
21
22
23 including all patients admitted to and treated by the surgical service, with or without
24
25
26 documented surgical intervention, this study found that 70 per 1000 surgical admissions
27
28
29 had a diagnosis of malignancy that was pathologically confirmed.
30
31
32
33
34

35 When further investigating categories of surgical procedure, the highest
36
37
38 incidence of malignancy was found to be in those undergoing inpatient breast
39
40
41 procedures. 95.2% (79/83) of all breast procedures resulted in a diagnosis of breast
42
43
44 cancer. Of those with a diagnosis of breast cancer, 97.5% were female with an average
45
46
47 age of 54 years old (SD 13.44).
48
49
50
51

52 A total of 119 colon, rectal, and anal procedures were performed from 2015-2017
53
54
55 resulting in 49 with a confirmed malignant diagnosis. This means that 41.2% of all
56
57
58
59
60

1
2
3 colon, rectal, and anal procedures were ultimately performed for malignant disease. The
4
5
6
7 majority of these cancers were determined to be colon adenocarcinoma (29/49), 15/49
8
9
10 were for adenocarcinoma located in the rectum, 3/49 were performed for squamous cell
11
12
13 carcinoma of the anus, and 2/49 were indeterminate recto-anal malignancy. Colorectal
14
15
16 cancers were evenly distributed between males and females with a slight female
17
18
19 predominance (42.9% and 55.1% respectively). Those who were diagnosed with
20
21
22 colorectal malignancy were on average older with a mean age of 55.1 years (SD 16.4)
23
24
25 compared to the mean age of 43.5 years (SD 18.23) of all those undergoing colon and
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

rectal surgical procedures.

Another surgical procedure found to have high rates of final malignant diagnosis
were gastric procedures, with 30.4% (17/56) of all gastric procedures performed during
this time period resulting in malignant diagnosis. Of the 17 patients with pathologic
evidence of gastric malignancy, there was similar incidence in male and female
patients. The mean age of patients diagnosed with gastric malignancy was 58.3 (SD
19.77) compared to 51.4 (SD 20.37) in those undergoing all gastric surgical procedures.

1
2
3
4 The remaining types of procedures had malignancy rates of 10.3% (14/136) for
5
6
7 all thyroid procedures, 8.8% (5/57) of all biliary procedures, 8.3% (21/253) of all soft
8
9
10 tissue procedures, and less than 1% (12/1,239) of all other procedures resulting in a
11
12
13 malignant diagnosis. Demographic information regarding age and gender can be seen
14
15
16
17 in **Table 2**.
18
19
20

21 Further investigation into patients with an admitting diagnosis of breast disease,
22
23
24 including individuals with breast cancer, breast abscess, breast cyst, and breast lumps,
25
26
27 is presented in **Table 3**. There were 145 patients admitted with a diagnosis related to
28
29
30 breast disease with 57.2% (83/145) known to have breast cancer or suspected to have
31
32
33 breast cancer based on physical exam resulting in an admitting diagnosis of “breast
34
35
36 cancer”. Of the 83 patients with an admitting diagnosis of breast cancer, 81.0% (68/83)
37
38
39 had surgical treatment with mastectomy. No documented surgical procedure was
40
41
42 performed in 13.1% (11/84) of those admitted with a diagnosis of breast cancer.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Discussion:
57
58
59
60

1
2
3
4 The findings from this study represent important data that can be used locally,
5
6
7 regionally, and nationally to better identify and treat patients with oncologic disease and
8
9
10 allocate limited medical resources. Specifically, at ERH the results from this study can
11
12
13
14 be used by physicians treating individual patients as well as by administration for
15
16
17 resource planning. Given that a majority of patients with final malignant disease were
18
19
20 suspected to have benign disease preoperatively based upon admitting diagnosis, the
21
22
23 knowledge of incidence of malignancy and demographic information presented in this
24
25
26
27 study could be used to guide surgeon decision making about operative intervention on
28
29
30 possible malignant disease. For example, awareness that currently greater than 30% of
31
32
33
34 all gastric procedures that are performed at ERH are for malignancy and that malignant
35
36
37 diagnosis was found more often in older patients allows for consideration of further
38
39
40
41 diagnostic work-up or referral to oncology prior to surgical intervention. On a larger
42
43
44 health system scale, given the high burden of cancer at ERH demonstrated by this
45
46
47
48 study, future development of local chemotherapy and radiation therapy programs should
49
50
51
52 be considered a priority.
53
54
55
56
57
58
59
60

1
2
3
4 Without an existing uniform population-based cancer registry system in Ghana
5
6
7 (11), distribution of resources and development of medical infrastructure to enhance
8
9
10 access to treatment of cancer is challenging. Unfortunately, formal population-based
11
12
13 cancer registries are associated with significant cost and time to develop. Because of
14
15
16 this, LMIC countries such as Ghana must often rely on basic estimates of cancer
17
18
19 burden when developing plans for the distribution and development of systems focused
20
21
22 on cancer treatment (18). While there have been significant advancements regarding
23
24
25 planned development of cancer registries in primarily large, urban hospitals (9) such as
26
27
28 those in Kumasi (10) and Accra (19), the burden of malignancy faced by smaller
29
30
31 suburban and rural hospitals, with extremely limited resources, is unknown and is
32
33
34 unlikely to be captured by formal cancer registries for the foreseeable future. With this
35
36
37 in mind, this study demonstrates the current need for cancer resources in the Eastern
38
39
40
41
42
43
44 Region of Ghana. Today patients who require specialized oncologic care must travel to
45
46
47
48 another region for care, with a majority of patients from ERH referred to Korle Bu for
49
50
51 treatment. These facilities are hours away from the patient's home and treatment is
52
53
54
55 often delayed due to the high volume of patients that are referred to these limited
56
57
58
59
60

1
2
3 specialized centers. With no regional access to oncology care, many patients are
4
5
6
7 treated with systemic chemotherapy prescribed and managed by the operating surgeon
8
9
10 at ERH, which likely accounts for the patients admitted to the surgical service with a
11
12
13 diagnosis of breast cancer who then did not undergo any surgical procedure observed
14
15
16 in this study. This study demonstrates that small, regional hospitals have a substantial
17
18
19 and diverse oncologic burden, and are in dire need of infrastructure, resources, and
20
21
22 specialized personnel to treat patients diagnosed with cancer.
23
24
25
26
27

28 While this study contains important data regarding the burden of malignancy in
29
30
31 this geographic area, there are limitations that must be considered when interpreting
32
33
34 this data. As there is currently no existing cancer registry capturing malignancies
35
36
37 treated in this region, we do not have access to many demographic, oncologic,
38
39
40 treatment, and overall survival data. This additional information would be helpful for
41
42
43 further planning and resource utilization. Additionally, while a majority of patients
44
45
46 presenting with malignancy are admitted to and treated by the surgical service, this
47
48
49 study does not capture cancer patients treated by other specialties, most notably
50
51
52
53
54
55
56
57
58
59
60
gynecological cancers. Because this is a hospital-based study and not a population

1
2
3 study, this study cannot account for patients in the region who did not seek care at ERH
4
5
6
7 for their malignancy. This has the potential to bias our results in unpredictable ways,
8
9
10 especially if the decision to not seek medical care was different among different groups.
11
12
13
14 For example, if elderly patients were less likely to seek care compared to younger
15
16
17 patients or if uninsured patients were less likely to seek care compared to patients with
18
19
20 health insurance this could lead to lower estimation of median age or under estimation
21
22
23 of incidence of cancer diagnoses. In addition, patients admitted to the surgical service
24
25
26 with obvious advanced or metastatic disease are not considered surgical candidates,
27
28
29 and are not accounted for in these data. Lastly, because patients must transport and
30
31
32 pay additional fees in order to obtain pathology results, there are pathologic specimens
33
34
35 that are never examined and recorded. Currently, it is estimated that about 20% of all
36
37
38 specimens that surgeons request pathologic evaluation do not undergo pathologic
39
40
41 evaluation due to patient noncompliance or inability to afford the extra associated fee.
42
43
44
45 Missing pathologic results could lead to underestimation of the true incidence of
46
47
48
49 malignancy treated surgically at ERH.
50
51
52
53
54
55
56
57
58
59
60

Conclusion:

This is the first study to investigate the cancer burden in Ghana's Eastern Region. This study reveals that over 13% of all surgical interventions were performed in patients with malignant disease. Rates of malignant diagnosis vary by type of procedure performed, but are very high in patients undergoing breast, colorectal, and gastric procedures. This study is a preliminary evaluation demonstrating the substantial cancer burden in the Eastern Region of Ghana and the burden of oncologic disease on general surgeons. Information from this study can be used to improve access to oncologic directed treatments in this region and plan future studies to further evaluate the burden of cancer and cancer related diseases at local and regional healthcare facilities in Sub-Saharan Africa.

List of Abbreviations:

LMIC-low-and-middle income countries

IARC-International Agency for Cancer Research

ERH-Eastern Regional Hospital

SD- Standard Deviation

1
2
3
4
5
6
7 • Authors' contributions
8
9

10 EO was involved in study design, data collection, data analysis, interpretation of
11 data, majority of manuscript authorship, and critical review and editing of
12 manuscript
13

14
15 PS was involved in study design, data collection, data analysis, interpretation of
16 data, and critical review and editing of manuscript
17

18
19 JD was involved in study design, data collection, data analysis, critical review
20 and editing of manuscript
21

22
23 WW was involved in study design, data collection, data analysis, critical review
24 and editing of manuscript
25

26
27 KS was involved in study design, data collection, data analysis, critical review
28 and editing of manuscript
29

30
31 RO was involved in interpretation of data, critical review and editing of
32 manuscript.

33
34 FA was involved in study design, interpretation of data, critical review and editing
35 of manuscript, and supervised the entirety of the project.

36
37 CP was involved in study design, interpretation of data, critical review and editing
38 of manuscript, and supervised the entirety of the project.
39
40

41
42 All authors read and approved the final manuscript
43
44
45

46
47 • Acknowledgements
48

49
50 Not Applicable
51
52
53
54
55
56
57
58
59
60

References:

1. Shah SC, Kayamba V, Peek RM, Heimburger D. Cancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening? *J Glob Oncol*. 2019;5:1-8.
2. The Global Cancer Burden American Cancer Society 2020 [Available from: <https://www.cancer.org/health-care-professionals/our-global-health-work/global-cancer-burden.html>].
3. National Policy for the Prevention and Control of Chronic Non-Communicable Disease in Ghana Ministry of Health 2012 [Available from: [https://www.iccp-portal.org/sites/default/files/plans/national_policy_for_the_prevention_and_control_of_chronic_non-communicable_diseases_in_ghana\(1\).pdf](https://www.iccp-portal.org/sites/default/files/plans/national_policy_for_the_prevention_and_control_of_chronic_non-communicable_diseases_in_ghana(1).pdf)].
4. de-Graft Aikins A, Addo J, Ofei F, Bosu W, Agyemang C. Ghana's burden of chronic non-communicable diseases: future directions in research, practice and policy. *Ghana Med J*. 2012;46(2 Suppl):1-3.
5. Global Burden of Disease Cause Patterns 2016 Institute for Health Metrics and Evaluation [Available from: <https://vizhub.healthdata.org/gbd-compare/>].
6. Ferlay J SI, Ervik M, et al. Cancer Incidence and Mortality Worldwide [Available from: <https://gco.iarc.fr/tomorrow/home>].
7. National Program of Cancer Registries Cancer Surveillance System Rationale and Approach. In: Control CfD, editor. 1999.
8. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. *Int J Cancer*. 2015;137(9):2060-71.
9. Yarney J, Ohene Oti NO, Calys-Tagoe BNL, Gyasi RK, Agyeman Duah I, Akoto-Aidoo C, et al. Establishing a Cancer Registry in a Resource-Constrained Region: Process Experience From Ghana. *JCO Glob Oncol*. 2020;6:610-6.
10. O'Brien KS, Soliman AS, Awuah B, Jiggae E, Osei-Bonsu E, Quayson S, et al. Establishing effective registration systems in resource-limited settings: cancer registration in Kumasi, Ghana. *J Registry Manag*. 2013;40(2):70-7.
11. Laryea DO, Awuah B, Amoako YA, Osei-Bonsu E, Dogbe J, Larsen-Reindorf R, et al. Cancer incidence in Ghana, 2012: evidence from a population-based cancer registry. *BMC Cancer*. 2014;14:362.
12. Amoako YA, Awuah B, Larsen-Reindorf R, Awittor FK, Kyem G, Ofori-Boadu K, et al. Malignant tumours in urban Ghana: evidence from the city of Kumasi. *BMC Cancer*. 2019;19(1):267.
13. Paul Opoku BA, Kofi Nyarko. Cancer Registration in Low-Resourced Settings: Practice and Recommendations. *Afr J Haematol Oncol*. 2010;1(4):129-37.
14. Kitcher E, Yarney J, Gyasi R, Cheyuo C. Laryngeal cancer at the korle bu teaching hospital accra ghana. *Ghana Med J*. 2006;40(2):45-9.
15. Clegg-Lampsey J, Hodasi W. A study of breast cancer in korle bu teaching hospital: assessing the impact of health education. *Ghana Med J*. 2007;41(2):72-7.
16. Martei YM, Vanderpuye V, Jones BA. Fear of Mastectomy Associated with Delayed Breast Cancer Presentation Among Ghanaian Women. *Oncologist*. 2018;23(12):1446-52.
17. Espina C, McKenzie F, Dos-Santos-Silva I. Delayed presentation and diagnosis of breast cancer in African women: a systematic review. *Ann Epidemiol*. 2017;27(10):659-71.e7.
18. Hanna TP, Kangolle AC. Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency. *BMC Int Health Hum Rights*. 2010;10:24.
19. Calys-Tagoe BN, Yarney J, Kenu E, Amanhyia NA, Enchill E, Obeng I. Profile of cancer patients' seen at Korle Bu teaching hospital in Ghana (a cancer registry review). *BMC Res Notes*. 2014;7:577.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1. Flow Chart of patients included in study.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Table 1. Demographic Features of Patients Undergoing Any Surgical Procedures

	Gastric Procedure (N=56)	Soft Tissue Procedure (N=253)	Biliary/Hepatic Procedure (N=57)	Colon/Rectal Procedure (N=119)	Breast Procedure (N=83)	Thyroid Procedure (N=136)	Other Procedure (N=1,239)
Gender							
FEMALE	19 (33.9%)	94 (37.2%)	37 (64.9%)	24 (20.2%)	80 (96.4%)	126 (92.6%)	433 (34.9%)
MALE	37 (66.1%)	159 (62.8%)	20 (35.1%)	95 (79.8%)	3 (3.6%)	10 (7.4%)	806 (65.1%)
Age							
Mean (SD)	51.4 (20.37)	47.3 (21.73)	52.6 (20.24)	43.5 (18.23)	54.0 (13.44)	47.0 (13.10)	40.6 (20.40)
Median	58.0	45.0	51.0	42.0	54.0	47.0	38.0
Interquartile range	35.5, 65.5	31.0, 66.0	40.0, 68.0	30.0, 52.0	46.0, 61.0	38.0, 57.5	25.0, 55.0

55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic Features of Patients Undergoing Any Surgical Procedures

	Gastric Procedure (N=56)	Soft Tissue Procedure (N=253)	Biliary/Hepatic Procedure (N=57)	Colon/Rectal Procedure (N=119)	Breast Procedure (N=83)	Thyroid Procedure (N=136)	Other Procedure (N=1,239)
Range	(0.0-88.0)	(1.0-94.0)	(7.0-96.0)	(5.0-97.0)	(15.0-94.0)	(16.0-83.0)	(0.0-140.0)
Insurance Status							
No	15 (26.8%)	45 (17.8%)	9 (15.8%)	41 (34.5%)	15 (18.1%)	7 (5.1%)	504 (40.7%)
Yes	41 (73.2%)	208 (82.2%)	48 (84.2%)	78 (65.5%)	68 (81.9%)	129 (94.9%)	735 (59.3%)

For peer review only

Table 2. Demographic Features of All Patients with Malignant Diagnosis

	Gastric	Soft Tissue	Biliary/Hepatic	Colon/Rectal	Breast	Thyroid	Other	Total
Number	17	21	5	49	79	14	12	261
Gender								
Female	9 (52.9%)	11 (52.4%)	2 (40%)	27 (55.1%)	77 (97.5%)	13 (92.9%)	7 (58.3%)	
Male	8 (47%)	10 (47.6%)	3 (60%)	21 (42.9%)	2 (2.5%)	1 (7.1%)	5 (41.7%)	
Age								
Mean (SD)	58.3 (19.77)	49.2 (16.3)	56.6 (6.4)	55.1 (16.4)	50.0 (14.7)	44.7 (14.8)	54.3 (21.6)	

Table 2. Demographic Features of All Patients with Malignant Diagnosis

	Gastric	Soft Tissue	Biliary/Hepatic	Colon/Rectal	Breast	Thyroid	Other	Total
Median	59.5	48.0	57	58	48	44	53	
Range	(28-97)	(29-80)	(45-63)	(15-85)	(4-79)	(13-68)	(20-94)	

For peer review only

Table 3. Details of those with admitting diagnosis related to breast disease

Admitting Diagnosis	
Breast Abscess	145
Breast Cyst	29
Breast Lump	5
Breast Cancer	28
	83

Table 3. Details of those with admitting diagnosis related to breast disease

Surgical Procedure Performed for those with Breast Cancer	83
Mastectomy	68 (81.0%)
Chest Tube Placement	1 (1.2%)
Emergency Tracheostomy	1 (1.2%)
Palliative Excisional Procedure	3 (3.8%)
No Surgical Procedure	11 (13.1%)




Figure 1. Flow Chart of patients included in study.

Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Page
	Reporting Item	Number
Title and abstract		
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1

1	Abstract	#1b	Provide in the abstract an informative and balanced summary	2
2				
3				
4			of what was done and what was found	
5				
6	Introduction			
7				
8				
9				
10	Background /	#2	Explain the scientific background and rationale for the	4
11	rationale		investigation being reported	
12				
13				
14				
15	Objectives	#3	State specific objectives, including any prespecified	5
16			hypotheses	
17				
18				
19				
20	Methods			
21				
22				
23	Study design	#4	Present key elements of study design early in the paper	6
24				
25				
26	Setting	#5	Describe the setting, locations, and relevant dates, including	6
27			periods of recruitment, exposure, follow-up, and data	
28			collection	
29				
30				
31	Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of	6
32			selection of participants.	
33				
34				
35				
36				
37				
38				
39				
40		#7	Clearly define all outcomes, exposures, predictors, potential	6
41			confounders, and effect modifiers. Give diagnostic criteria, if	
42			applicable	
43				
44				
45				
46				
47	Data sources /	#8	For each variable of interest give sources of data and details	6
48	measurement		of methods of assessment (measurement). Describe	
49			comparability of assessment methods if there is more than	
50			one group. Give information separately for for exposed and	
51			unexposed groups if applicable.	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Bias	#9	Describe any efforts to address potential sources of bias	11
2				
3				
4	Study size	#10	Explain how the study size was arrived at	7
5				
6				
7	Quantitative	#11	Explain how quantitative variables were handled in the	6
8	variables		analyses. If applicable, describe which groupings were	
9			chosen, and why	
10				
11				
12				
13				
14				
15	Statistical	#12a	Describe all statistical methods, including those used to	6
16	methods		control for confounding	
17				
18				
19				
20	Statistical	#12b	Describe any methods used to examine subgroups and	6
21	methods		interactions	
22				
23				
24				
25				
26	Statistical	#12c	Explain how missing data were addressed	6
27	methods			
28				
29				
30				
31	Statistical	#12d	If applicable, describe analytical methods taking account of	6
32	methods		sampling strategy	
33				
34				
35				
36	Statistical	#12e	Describe any sensitivity analyses	6
37	methods			
38				
39				
40				
41				
42	Results			
43				
44				
45	Participants	#13a	Report numbers of individuals at each stage of study—eg	7
46			numbers potentially eligible, examined for eligibility,	
47			confirmed eligible, included in the study, completing follow-	
48			up, and analysed. Give information separately for for	
49			exposed and unexposed groups if applicable.	
50				
51				
52				
53				
54				
55				
56				
57	Participants	#13b	Give reasons for non-participation at each stage	7
58				
59				
60				

1	Participants	#13c	Consider use of a flow diagram	7
2				
3				
4	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	7
5			clinical, social) and information on exposures and potential	
6			confounders. Give information separately for exposed and	
7			unexposed groups if applicable.	
8				
9				
10				
11				
12				
13				
14	Descriptive data	#14b	Indicate number of participants with missing data for each	7
15			variable of interest	
16				
17				
18				
19	Outcome data	#15	Report numbers of outcome events or summary measures.	7
20			Give information separately for exposed and unexposed	
21			groups if applicable.	
22				
23				
24				
25				
26				
27	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-	7
28			adjusted estimates and their precision (eg, 95% confidence	
29			interval). Make clear which confounders were adjusted for	
30			and why they were included	
31				
32				
33				
34				
35				
36				
37	Main results	#16b	Report category boundaries when continuous variables were	8
38			categorized	
39				
40				
41				
42	Main results	#16c	If relevant, consider translating estimates of relative risk into	8
43			absolute risk for a meaningful time period	
44				
45				
46				
47				
48	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups	8
49			and interactions, and sensitivity analyses	
50				
51				
52				
53	Discussion			
54				
55				
56	Key results	#18	Summarise key results with reference to study objectives	10
57				
58				
59				
60				

1	Limitations	#19	Discuss limitations of the study, taking into account sources	11
2			of potential bias or imprecision. Discuss both direction and	
3			magnitude of any potential bias.	
4				
5				
6				
7				
8				
9	Interpretation	#20	Give a cautious overall interpretation considering objectives,	11
10			limitations, multiplicity of analyses, results from similar	
11			studies, and other relevant evidence.	
12				
13				
14				
15				
16	Generalisability	#21	Discuss the generalisability (external validity) of the study	11
17			results.	
18				
19				
20				
21				
22	Other Information			
23				
24				
25	Funding	#22	Give the source of funding and the role of the funders for the	3
26			present study and, if applicable, for the original study on	
27			which the present article is based	
28				
29				
30				
31				
32				

33 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License
34 CC-BY. This checklist was completed on 26. March 2021 using <https://www.goodreports.org/>, a tool
35 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60